March 25th 2024
A new study finds that the use of continuous glucose monitoring helps reduce complications from type 1 diabetes, lowering the risk of developing or progressing diabetic retinopathy.
REMS now available for Avandia; access to drug restricted
June 3rd 2011FDA announced May 18 to the public new restrictions to the prescribing, dispensing, and use of rosiglitazone-containing medications (Avandia, Avandamet, and Avandaryl, GlaxoSmithKline [GSK]) as part of a Risk Evaluation and Mitigation Strategy.
Read More
Trilipix to stay on market, but FDA panel recommends new study
June 3rd 2011An FDA advisory panel recommended fenofibric acid (Trilipix, Abbott) still be marketed for use but voted unanimously that Abbott be required to conduct a new study to determine whether a Trilipix-statin combination reduces heart attacks.
Read More
Antihyperglycemic agents useful as third agent, but class preference unclear
June 3rd 2011There is no clear difference in benefit between drug classes when adding an antihyperglycemic as a third agent to the treatment of patients with type 2 diabetes who are already receiving metformin and a sulfonylurea, according to a meta-analysis published in the May 17 issue of Annals of Internal Medicine.
Read More
Academy of Managed Care Pharmacy: Cancer, diabetes, cardiovascular agents fill pipeline
June 1st 2011The pipeline continues to decline from 4 to 5 years ago where smaller molecules led the way, according to a current state of the pharmaceutical pipeline presentation at the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase in Minneapolis.
Read More
Breaking News: Diabetes, specialty drugs continue to drive growth in drug spending
May 18th 2011For the fourth consecutive year, diabetes therapy topped the list of contributors to drug use trends in therapeutic categories, contributing 16.1% to overall growth in drug spending in 2010 due to an increasing number of patients, according to the recently released 2011 Medco Drug Trend Report, which tracks utilization and spending.
Read More
Consider ER oxymorphone in patients with chronic low back pain, comorbidities
May 6th 2011In patients with chronic low back pain with comorbidities such as hypertension, diabetes, and cardiovascular disease, extended-release oxymorphone (Opana ER, Endo Pharmaceuticals) may be a safe and effective alternative, according to a study presented at the annual meeting of the American Academy of Pain Medicine, National Harbor, Md.
Read More
Intensive glycemic management leads to higher mortality in type 2 diabetes mellitus patients
April 1st 2011The management of type 2 diabetes mellitus needs to change in response to the evolving evidence base now available. Research from the ADVANCE and the ACCORD trials was presented during the American Diabetes Association 58th annual advanced postgraduate course in New York City.
Read More
Rosiglitazone label and medication guide updated with cardiovascular risks
February 18th 2011FDA has announced that the physician labeling and patient medication guide for rosiglitazone (Avandia, GlaxoSmithKline) have been changed to include information on cardiovascular risks (including death) of this agent.
Read More
FDA sends complete response letter to MannKind regarding new inhaler
January 28th 2011FDA has sent MannKind Corp. a complete response letter regarding the company?s NDA for Afrezza Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes for the control of hyperglycemia.
Read More
Angiotensin receptor blockers may not reduce mortality in diabetes, hypertension settings
January 1st 2011Antihypertensive therapy with an angiotensin receptor blocker is not associated with reductions in cardiovascular or all-cause mortality compared to non-ARB-based regimens in patients with type 2 diabetes, according to researchers at the Massachusetts College of Pharmacy and Health Sciences.
Read More
Kombiglyze XR tablets approved for the treatment of type 2 diabetes mellitus in adults
December 20th 2010FDA has approved saxagliptin and metformin XR (Kombiglyze XR, AstraZeneca and Bristol-Myers Squibb) tablets for the treatment of type 2 diabetes in adults. Kombiglyze XR is the first and only once-a-day metformin XR plus DPP-4 inhibitor combination tablet offering strong glycaemic control across glycosylated hemoglobin levels, fasting plasma glucose and post-prandial glucose.
Read More
Paricalcitol found to reduce albuminuria in type 2 diabetes
December 10th 2010In a multinational, placebo-controlled, double-blind trial, the selective vitamin D receptor activator paricalcitol (Zemplar, Abbott Laboratories), at doses of 1 µg or 2 µg daily, reduced albuminuria in patients with type 2 diabetes, who were already being treated with renin-angiotensin-aldosterone system inhibitors.
Read More
Metformin may lower mortality in patients with diabetes and heart failure
December 10th 2010Metformin, either alone or in combination with sulfonylurea, appears to increase 1-year and long-term survival in patients with type 2 diabetes mellitus and chronic heart failure, according to research published in the October 1 issue of the American Journal of Cardiology, HealthDay News reported.
Read More
Glitazones for diabetes prevention found superior to other oral antidiabetic drug classes
July 1st 2010A systematic review assessing the comparative effectiveness of oral antidiabetic drugs for preventing patients at high risk from progressing to type 2 diabetes has found glitazones, biguanides, and alpha-glucosidase inhibitors reduced the relative risk of diabetes by as much as 63%, whereas insulin secretagogues had no effect.
Read More
Liraglutide: A human GLP-1 analogue for the treatment of type 2 diabetes
May 1st 2009Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue that is currently pending FDA approval for the treatment of type 2 diabetes. This agent mimics the actions of food-induced endogenous GLP-1 release, thus causing glucose-dependent increased insulin secretion, decreased glucagon secretion, and reduced appetite and gastric emptying.
Read More
Metformin moderately protective against CV risk in type 2 diabetics
November 13th 2008Compared with biguanides, thiazolidinediones, meglitinides, and second-generation sulfonylureas, metformin is the sole oral therapy associated with a decreased risk of cardiovascular (CV) mortality in patients with type 2 diabetes, according to a meta-analysis published in the Archives of Internal Medicine.
Read More
Diabetes treatment becoming more complex, more expensive
November 13th 2008In a survey of trends in diabetes treatment from 1994 to 2007, investigators observed an increasing incidence of diabetes, a greater variety of drugs and combinations available for treatment, and a marked increase in the annual cost of diabetes medications.
Read More
Alogliptin: A dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes
September 1st 2008Alogliptin is a highly selective DPP-IV inhibitor under investigation for the treatment of type 2 diabetes. An NDA for alogliptin was submitted in January 2008, and a response from FDA is expected in the fourth quarter of this year.
Read More